Business Wire

IMPROVE

28.9.2021 14:03:13 CEST | Business Wire | Press release

Share
To Support European Healthcare Systems Post COVID-19, ImPrOve Experts Call for Improved Perioperative Monitoring to Optimise Patient Safety

The Improving Patient Outcomes (ImPrOve) Think Tank, a group of anaesthetists, surgeons and patient representatives, today launched its European Report to address a serious public health issue – death and serious complication rates in the 30-days after high-risk surgery remain high.i In an effort to improve patient safety and outcomes, the Report calls for better physician training on the latest guidelines, funding for modern digital monitoring, greater use of data from modern technologies in health policies and the right for patients to be involved in dialogue about the management of their procedure.

In Europe, 2.4 million patients undergo high-risk surgery every year.ii,iii Evidence from the UK suggests that 80% of postoperative deaths occur in a 10% sub-population of high-risk patients. If this trend continued at a European level, potentially 192,000 will die in the 30-day period after surgery.i While there are many challenges in high-risk surgery, the most alarming complication for the ImPrOve Think Tank is haemodynamic instability, manifested as drops in blood pressure, and known as IOH.i

During high-risk surgery it is vital that blood continues to flow to organs. IOH is common during surgery under general anaesthesia, occurring in up to 99% of patients.i It has the potential to cause tissue damage in any vital organ, but the heart and kidneys are most affected. Recent studies show associations between IOH and increased risk of acute kidney injury (AKI) and myocardial injury iv,v – the leading cause of post-operative mortality.

Postsurgical patients with AKI and myocardial injury stay longer in hospital, have higher readmission rates, and cost more to care for.iv The subsequent financial impact of this also has a significant impact on European healthcare systems. However, if haemodynamic instability is effectively monitored and prevented, these serious complications can be avoided, and patient outcomes can be significantly improved.

“Our mission is to work collaboratively with patient representatives, clinicians and policy makers to improve perioperative patient safety and experience with the help of advanced haemodynamic monitoring technologies”, commented Professor Olivier Huet, ImPrOve Chair and Professor of Anaesthesia and Intensive Care Medicine. “Major gaps still exist in reducing the risk of complications after high-risk surgery across European hospitals, working together is therefore imperative. All stakeholders need to be onboard so that we can create change and address the calls to action.”

By 2050, it is predicted that 1 in 4 people could be over 65.vi With haemodynamic instability reported as high as 83% in more senior patients,vii the ImPrOve Think Tank believe it will be a likely cause of a significant proportion of modifiable postoperative mortality and morbidity in Europe.

“Patients are often unaware of the risks of not receiving innovative digital monitoring technology, so they may not ask for the best perioperative management”, said Ms Luciana Valente, International Relations Manager at SIHA, Italy, and member of the Think Tank. “It is essential that patients are better informed of the key risks associated with their procedure and aware that the use of innovative digital monitoring, and other actions will be taken to mitigate these risks. The more a patient is invested in a procedure, the better the outcomes will be.”

For further information and to download ‘Improving patient safety: why perioperative care and effective monitoring matters” please visit www.improvethinktank.org

References


i Pearse RM, Moreno RP, Bauer P, Pelosi P, Metnitz P, Spies C et al . Mortality after surgery in Europe: a 7-day cohort study. Lancet. 2021; Sep 22;380(9847):1059-65. Available at: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61148-9/fulltext [accessed July 2021].

ii Preoperative Score to Predict Postoperative Mortality – POSPOM Edward’s Presentation

iii Ghaferi, et al. Variation in Hospital Mortality Associated with Inpatient Surgery. N Engl J Med, 2009.

iv Keuffel EL, Rizzo J, Stevens M, Gunnarsson C, Maheshwari K. Hospital costs associated with intraoperative hypotension among non-cardiac surgical patients in the US: a simulation model. J Med Econ. 2019 Jul;22(7):645-651. Available at: https://www.tandfonline.com/doi/full/10.1080/13696998.2019.1591147 [accessed July 2021]

v Wesselink EM, Kappen TH, Torn HM, Slooter AJC, van Klei WA. Intraoperative hypotension and the risk of postoperative adverse outcomes: a systematic review. Br J Anaesth. 2018 Oct;121(4):706-721. Available at: https://bjanaesthesia.org/article/S0007-0912(18)30376-3/fulltext . [accessed July 2021].

vi United Nations. Ageing. 2019. Available at: https://www.un.org/en/sections/issues-depth/ageing/ [accessed July 2021]

vii Wickham A, Highton D, Martin D, The Pan London Perioperative Audit and Research Network. Care of elderly patients: a prospective audit of the prevalence of hypotension and the use of BIS intraoperatively in 25 hospitals in London. Perioper Med (Lond). 2016; 5: 12. Available at: (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4882849/ ) [accessed July 2021].

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Garvan Institute of Medical Research Joins Parse Biosciences’ Certified Service Provider Network15.7.2026 22:00:00 CEST | Press release

Researchers across Asia-Pacific gain a new option for high-quality single cell sequencing through Garvan's Evercode WT services Parse Biosciences, a QIAGEN company, and the leader in scalable and accessible single cell sequencing, today announced that the Genomics Platform Core Facility within the Garvan Institute of Medical Research has joined its Certified Service Provider (CSP) Program. The partnership broadens access to high-quality, scalable single cell sequencing across Australia, the wider Asia-Pacific region, and beyond. Garvan is one of Australia's preeminent medical research institutions, with the Genomics Platform having deep experience in cell sorting, capture, and sequencing. As a Certified Service Provider, Garvan will offer Parse's Evercode WT kits to researchers across the region. "We see a growing number of requests for Parse projects and find the technology easy to implement and run, generating great data," said Chris O'Keeffe, Cellular Genomics Lead at the Garvan Ins

Grafana Labs Named a Leader in 2026 Gartner® Magic Quadrant™ for Observability Platforms and Positioned Furthest in Completeness of Vision15.7.2026 20:21:00 CEST | Press release

Named a Leader for the third consecutive year and placed furthest in vision for the second year in a row, the company has had a landmark year of innovation as observability becomes essential infrastructure for teams building and running AI at scale. Grafana Labs, the company behind the open observability cloud, today announced it has been named a Leader in the Gartner® Magic Quadrant™ for Observability Platforms for the third consecutive year, and positioned furthest on the Completeness of Vision axis for the second year running. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260715814984/en/ 2026 Gartner® Magic Quadrant™ for Observability Platforms We believe this placement reflects where the market is headed: toward open, composable observability that helps teams in the AI era understand systems that are increasingly complex and agentic, and rapidly scaling thanks to AI-assisted engineering. A Platform Built for the AI Era

Spectro Cloud Raises $100 Million Series D to Help Customers Move AI Infrastructure Into Production Across Enterprise, Public Sector, Neocloud and Sovereign Cloud Environments15.7.2026 18:20:00 CEST | Press release

Growth Equity at Goldman Sachs Alternatives leads oversubscribed round with strategic participation from AMD Ventures, Ericsson, LG Technology Ventures, and Maximus as organizations look to turn AI silicon into business outcomes Spectro Cloud, a leading provider of AI infrastructure management software, today announced it has raised more than $100 million in an oversubscribed Series D funding round led by Growth Equity at Goldman Sachs Alternatives, with strategic participation from AMD Ventures, Ericsson, LG Technology Ventures, and Maximus. The new funding brings Spectro Cloud’s total capital raised to $260 million and will accelerate the company’s mission to help enterprises, public sector organizations, neoclouds and sovereign clouds build and operate production AI infrastructure with greater control over cost, security and governance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260715551858/en/ Spectro Cloud raises $

K-Beauty Goes Global: Sales Surge 53% as Korean Innovation Reshapes Beauty Growth15.7.2026 16:00:00 CEST | Press release

New NIQ data shows K-Beauty value sales rose 53% year-over-year and 131% over two years, underscoring how regional beauty trends, social commerce and ingredient-led innovation are reshaping global beauty growth. NIQ (NYSE: NIQ), a global leader in consumer intelligence, today released new findings showing K-Beauty has become a rapidly growing global beauty segment, with value sales up 53% year-over-year and 131% over the past two years. The data points to a broader shift in beauty growth, as regional innovation, social commerce and digitally driven consumer demand increasingly shape what scales globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260715867578/en/ K-Beauty accelerates across global markets In its latest report, K-Beauty Goes Global, NIQ shows how Korean beauty is reshaping consumer expectations, accelerating innovation cycles and redefining competitive dynamics across the global beauty market. What began

Viz.ai to Support the MINUTE Trial, a Landmark Multicenter Study Evaluating the SCUBA Technique for the Treatment of Intracerebral Hemorrhage15.7.2026 15:00:00 CEST | Press release

Viz Neuro™ Suite, including Viz ICH™ and Viz ICH Plus™, to facilitate rapid detection and care coordination for patients with basal ganglia hemorrhage across trial sites nationwide. Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced its support for the Minimally Invasive Neurosurgery Trial for Ultra-early Treatment (MINUTE) Trial, a prospective, multicenter, randomized study evaluating whether the SCUBA technique, an endoscopic, catheter-based approach for ultra-early evacuation of basal ganglia intracerebral hemorrhage (BGH), is a promising alternative to standard medical management to potentially improve functional patient outcomes. The study aims to initiate both randomization and surgical intervention within 120 minutes of key clinical time points, reflecting the urgent nature of intracerebral hemorrhage care. Participating sites will have the ability to leverage the Viz Neuro Suite platform, including Viz ICH and Viz ICH Plus, to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye